Investigational drug · Phase 3
MLC 901
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer's Disease Dementia.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
12
Any phase or sponsor naming "MLC 901"
First trial start
2026
Aug 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MLC 901", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer's Disease Dementia
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "MLC 901" as an intervention, largest first.
- NeuroAiD Safe Treatment RegistryStatus unknown
CHIMES SocietyAcademic, hospital or other
NCT02536079 · 2,000 participants (planned) · Start Jun 2014 · Primary completion Dec 2024
Drug: NeuroAiD · For: Brain Injury; NeuroAiD Use
Sites: Jakarta, Indonesia; Kuala Lumpur, Malaysia
- CHInese Medicine NeuroAid Efficacy on Stroke RecoveryPivotal-lookingCompleted
CHIMES SocietyAcademic, hospital or other
NCT00554723 · 1,100 participants · Start May 2007 · Primary completion Aug 2012
Drug: NeuroAid; NeuroAid matched Placebo · For: Cerebral Infarction; Stroke
Sites: Hong Kong, Hong Kong; George Town, Malaysia; Cebu City, Philippines · 24 sites in all
- Alzheimer's Disease THErapy With NEuroaid IIPivotal-lookingNot yet recruiting
Moleac Pte Ltd.Industry
NCT07191028 · 350 participants (planned) · Start Aug 2026 · Primary completion Feb 2029
Drug: MLC 901; Placebo · For: Alzheimer's Disease Dementia
Sites: Singapore, Singapore
- Clinical Study to Investigate the Safety and Efficacy of MLC601 in 150 Iranian Patients After StrokePivotal-lookingCompleted
Shahid Beheshti UniversityAcademic, hospital or other
NCT01336153 · 150 participants · Start Aug 2009 · Primary completion Jan 2010
Drug: MLC601; Placebo · For: Stroke
- The Alzheimer's Disease THErapy With NEuroaid (ATHENE) StudyPivotal-lookingStatus unknown
National University Hospital, SingaporeAcademic, hospital or other
NCT03038035 · 150 participants (planned) · Start Dec 2016 · Primary completion Jun 2018
Drug: MLC901; Placebo · For: Alzheimer Disease
Sites: Singapore, Singapore
Shahid Beheshti University of Medical SciencesAcademic, hospital or other
NCT01696123 · 125 participants · Start Jan 2011 · Primary completion Jan 2012
Drug: MLC601 · For: Alzheimer Disease
Sites: Tehran, Iran
- NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented SubjectsPivotal-lookingCompleted
National University Hospital, SingaporeAcademic, hospital or other
NCT01847924 · 103 participants · Start Mar 2013 · Primary completion Apr 2018
Drug: MLC901; Placebo · For: Cognitive Impairment
Sites: Manila, Philippines; Singapore, Singapore; Hanoi, Vietnam · 5 sites in all
Ali Amini HarandiAcademic, hospital or other
NCT04487275 · 80 participants (planned) · Start Aug 20, 2018 · Primary completion Sep 2020
Drug: MLC901 or Placebo · For: Traumatic Brain Injury
Sites: Tehran, Iran
EVD Pharmacy and Medical Company LimitedIndustry
NCT07828210 · 80 participants (planned) · Start Sep 10, 2026 · Primary completion Sep 2027
Drug: MLC901 · For: Stroke; Stroke, Acute Ischemic; Stroke, Ischemic and 2 more
Sites: Ho Chi Minh City, Vietnam
Moleac Pte Ltd.Industry
NCT00721825 · 40 participants · Start Jan 2008 · Primary completion Jul 2008
Drug: Neuroaid; Neuroaid matched Placebo · For: Stroke; Cerebral Infarction
Sites: Singapore, Singapore
Newest research
PubMed records naming it or its code names, newest first.
- The efficacy of MLC 901 in neuron-specific enolase, functional outcome and cerebral infarct volume for acute ischemic stroke model in rats.
Hunaifi I, Kurnia Bintang A, Tammasse J, et al. · Pak J Pharm Sci 2026
- Molecular Mechanism of MLC 901 in Acute Ischemic Stroke: A Review.
Hunaifi I, Bintang AK, Tammasse J, et al. · Stroke Res Treat 2025
- Evaluation of Neuroprotective and Neuroregenerative Potential of NeuroAiDࡊ II(MLC901) in a Rat Model of Kainic Acid-Induced Spinal Cord Injury.
Anjum A, Yazid MD, Daud MF, et al. · Mol Neurobiol 2025
- Increased levels of tumor necrosis factor-alpha in rat with traumatic brain injury after NeuroAid (MLC 901) administration.
Rohadi, Priyanto B, Islam AA, et al. · Surg Neurol Int 2025
- Mechanical scratch injury on differentiated motor neuron of NSC-34 cells as an in vitro model for evaluation of neuroregeneration potential of NeuroAiD II (MLC901).
Anjum A, Yazid MD, Daud MF, et al. · In Vitro Model 2024
- The role of MLC901 in reducing VEGF as a vascular permeability marker in rats with spinal cord injury.
Wahyudi, Islam AA, Hatta M, et al. · Ann Med Surg (Lond) 2022
Also in development for Alzheimer's Disease Dementia
- DiranersenISIS 814907, BIIB080Phase 21 trial
Biogen · Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.